CLAIMS

1. Use of irradiated microparticles in the manufacture of a medicament for the treatment of renal neoplastic conditions in a subject, wherein the irradiated microparticles are to be administered to the subject by selective internal radiation therapy (SIRT), and wherein (i) the irradiated microparticles have a prescribed activity of 0.02 to 3.5 GBq, (ii) the irradiated microparticles comprise yttrium-90 and (iii) the SIRT is configured to deliver between 200 and 800 Gy to a site of treatment in the kidney.

2. The use according to claim 1, wherein the site of treatment in the kidney is a kidney neoplasia.

3. The use according to claim 1 or 2, wherein the prescribed activity is capped at a maximum of 3 GBq.

4. The use according to claim 2 or 3, wherein activity of the irradiated microparticles used in the selective internal radiation therapy (SIRT) is calculated by determining tumour volume and then adjusting an amount of the irradiated microparticles to deliver to the kidney neoplasia a radiation dose between 200 and 800 Gy.